US8703764B2 - Combination therapy for dementia, depression and apathy - Google Patents
Combination therapy for dementia, depression and apathy Download PDFInfo
- Publication number
- US8703764B2 US8703764B2 US11/437,409 US43740906A US8703764B2 US 8703764 B2 US8703764 B2 US 8703764B2 US 43740906 A US43740906 A US 43740906A US 8703764 B2 US8703764 B2 US 8703764B2
- Authority
- US
- United States
- Prior art keywords
- apathy
- monoamine oxidase
- risperidone
- quetiapine
- sertindole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 206010002942 Apathy Diseases 0.000 title claims abstract description 74
- 206010012289 Dementia Diseases 0.000 title claims abstract description 57
- 238000002648 combination therapy Methods 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims abstract description 44
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims abstract description 41
- 239000000164 antipsychotic agent Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 25
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 98
- 229960001534 risperidone Drugs 0.000 claims description 97
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 91
- 229960005017 olanzapine Drugs 0.000 claims description 91
- 229960004431 quetiapine Drugs 0.000 claims description 86
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 86
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 86
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 86
- 229960000652 sertindole Drugs 0.000 claims description 85
- 229960000607 ziprasidone Drugs 0.000 claims description 85
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 85
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 84
- 229960004496 zotepine Drugs 0.000 claims description 84
- 229960004170 clozapine Drugs 0.000 claims description 83
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical group C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 44
- 229960004644 moclobemide Drugs 0.000 claims description 40
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 claims description 36
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 claims description 35
- 229940070023 iproniazide Drugs 0.000 claims description 33
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 claims description 25
- QNEXFJFTGQBXBJ-UHFFFAOYSA-N fenoxypropazine Chemical compound NNC(C)COC1=CC=CC=C1 QNEXFJFTGQBXBJ-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 229950000457 fenoxypropazine Drugs 0.000 claims description 22
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 claims description 19
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 19
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 claims description 19
- IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 claims description 18
- 230000002441 reversible effect Effects 0.000 claims description 17
- 229950004068 brofaromine Drugs 0.000 claims description 16
- 229960002309 toloxatone Drugs 0.000 claims description 16
- 229950000017 befloxatone Drugs 0.000 claims description 15
- CFOOTBBXHJHHMT-UHFFFAOYSA-N 4,4-diphenyl-1-propan-2-ylpiperidine Chemical compound C1CN(C(C)C)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 CFOOTBBXHJHHMT-UHFFFAOYSA-N 0.000 claims description 14
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 14
- CHDGAVDQRSPBTA-UHFFFAOYSA-N esuprone Chemical compound CC1=C(C)C(=O)OC2=CC(OS(=O)(=O)CC)=CC=C21 CHDGAVDQRSPBTA-UHFFFAOYSA-N 0.000 claims description 14
- MVVJINIUPYKZHR-UHFFFAOYSA-N 3-[[4-[5-(methoxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy]methyl]benzonitrile Chemical compound O=C1OC(COC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 MVVJINIUPYKZHR-UHFFFAOYSA-N 0.000 claims description 13
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims description 13
- QSQQPMHPCBLLGX-UHFFFAOYSA-N N-methyl-4-[2-(phenylmethyl)phenoxy]-1-butanamine Chemical compound CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1 QSQQPMHPCBLLGX-UHFFFAOYSA-N 0.000 claims description 13
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 claims description 13
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 claims description 13
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 claims description 13
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 13
- BBAZDLONIUABKI-UHFFFAOYSA-N 3-(2,4-dichlorophenoxy)-n-methyl-n-prop-2-ynylpropan-1-amine;hydrochloride Chemical compound Cl.C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BBAZDLONIUABKI-UHFFFAOYSA-N 0.000 claims description 12
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 claims description 12
- IBWPUTAKVGZXRB-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)butan-2-ylhydrazine Chemical compound NNC(C)CCC1=CC=C2OCOC2=C1 IBWPUTAKVGZXRB-UHFFFAOYSA-N 0.000 claims description 12
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 claims description 12
- HFQMYSHATTXRTC-JTQLQIEISA-N amiflamine Chemical compound C[C@H](N)CC1=CC=C(N(C)C)C=C1C HFQMYSHATTXRTC-JTQLQIEISA-N 0.000 claims description 12
- KRNDIPHOJLIHRI-UHFFFAOYSA-N bazinaprine Chemical compound N#CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 KRNDIPHOJLIHRI-UHFFFAOYSA-N 0.000 claims description 12
- BEWNZPMDJIGBED-UHFFFAOYSA-N benmoxin Chemical compound C=1C=CC=CC=1C(C)NNC(=O)C1=CC=CC=C1 BEWNZPMDJIGBED-UHFFFAOYSA-N 0.000 claims description 12
- 229960004933 bifemelane Drugs 0.000 claims description 12
- ZXUMUPVQYAFTLF-UHFFFAOYSA-N etryptamine Chemical compound C1=CC=C2C(CC(N)CC)=CNC2=C1 ZXUMUPVQYAFTLF-UHFFFAOYSA-N 0.000 claims description 12
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 claims description 12
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims description 12
- GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 claims description 12
- HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 claims description 12
- FODQIVGFADUBKE-UHFFFAOYSA-N octamoxin Chemical compound CCCCCCC(C)NN FODQIVGFADUBKE-UHFFFAOYSA-N 0.000 claims description 12
- 229960000964 phenelzine Drugs 0.000 claims description 12
- VXTWEDPZMSVFEF-UHFFFAOYSA-N pheniprazine Chemical compound NNC(C)CC1=CC=CC=C1 VXTWEDPZMSVFEF-UHFFFAOYSA-N 0.000 claims description 12
- 229960003946 selegiline Drugs 0.000 claims description 12
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 11
- LAUWCWCSEOWJMQ-QRJSTWQJSA-N (e,2s)-2-amino-4-fluoro-3-(3-hydroxyphenyl)but-3-enoic acid Chemical compound OC(=O)[C@@H](N)C(=C\F)\C1=CC=CC(O)=C1 LAUWCWCSEOWJMQ-QRJSTWQJSA-N 0.000 claims description 11
- HQSRQKBSOOZLHH-UHFFFAOYSA-N 1-ethylphenoxathiine 10,10-dioxide Chemical compound O1C2=CC=CC=C2S(=O)(=O)C2=C1C=CC=C2CC HQSRQKBSOOZLHH-UHFFFAOYSA-N 0.000 claims description 11
- XFDXQLJFMLWWJA-YVMONPNESA-N 3-[(e)-3-amino-1-fluoroprop-1-en-2-yl]phenol Chemical compound NC\C(=C\F)C1=CC=CC(O)=C1 XFDXQLJFMLWWJA-YVMONPNESA-N 0.000 claims description 11
- YKTSVZRWKHWINV-UHFFFAOYSA-N 4-[(7-hydroxy-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)amino]benzonitrile Chemical compound OC1CCC2=C1N=CN=C2NC1=CC=C(C#N)C=C1 YKTSVZRWKHWINV-UHFFFAOYSA-N 0.000 claims description 11
- 229950004939 amiflamine Drugs 0.000 claims description 11
- 229950005683 bazinaprine Drugs 0.000 claims description 11
- 229950011271 benmoxin Drugs 0.000 claims description 11
- 229950001660 cimoxatone Drugs 0.000 claims description 11
- 229950007673 esuprone Drugs 0.000 claims description 11
- 229950005957 etryptamine Drugs 0.000 claims description 11
- 229960001625 furazolidone Drugs 0.000 claims description 11
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 claims description 11
- 229960002589 iproclozide Drugs 0.000 claims description 11
- 229960002672 isocarboxazid Drugs 0.000 claims description 11
- 229950006217 mebanazine Drugs 0.000 claims description 11
- 229960003057 nialamide Drugs 0.000 claims description 11
- 229950006863 octamoxin Drugs 0.000 claims description 11
- 229960001779 pargyline Drugs 0.000 claims description 11
- 229950005573 pheniprazine Drugs 0.000 claims description 11
- FWWDFDMCZLOXQI-UHFFFAOYSA-N pivhydrazine Chemical compound CC(C)(C)C(=O)NNCC1=CC=CC=C1 FWWDFDMCZLOXQI-UHFFFAOYSA-N 0.000 claims description 11
- 229950008099 pivhydrazine Drugs 0.000 claims description 11
- 229950004405 prodipine Drugs 0.000 claims description 11
- FTKTZRKAVSDSRA-UHFFFAOYSA-N sercloremine Chemical compound C1CN(C)CCC1C1=CC2=CC(Cl)=CC=C2O1 FTKTZRKAVSDSRA-UHFFFAOYSA-N 0.000 claims description 11
- 229960003741 tranylcypromine Drugs 0.000 claims description 11
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 206010012218 Delirium Diseases 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 5
- 206010050013 Abulia Diseases 0.000 claims description 3
- 206010001541 Akinesia Diseases 0.000 claims description 3
- 208000000722 Akinetic Mutism Diseases 0.000 claims description 3
- 201000000251 Locked-in syndrome Diseases 0.000 claims description 3
- 229940091512 Monoamine oxidase A inhibitor Drugs 0.000 claims description 3
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract description 33
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract description 25
- 208000020016 psychiatric disease Diseases 0.000 abstract description 10
- 230000002354 daily effect Effects 0.000 description 67
- 238000011282 treatment Methods 0.000 description 31
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 28
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- 208000024714 major depressive disease Diseases 0.000 description 19
- 229960004688 venlafaxine Drugs 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 13
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 12
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- ZHFIAFNZGWCLHU-YPMHNXCESA-N ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 description 11
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 11
- 229960002296 paroxetine Drugs 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 11
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 10
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 10
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 10
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 10
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 10
- 206010026749 Mania Diseases 0.000 description 10
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 10
- -1 SSRIs Substances 0.000 description 10
- SXYFFMXPDDGOEK-UHFFFAOYSA-N binedaline Chemical compound C12=CC=CC=C2N(N(C)CCN(C)C)C=C1C1=CC=CC=C1 SXYFFMXPDDGOEK-UHFFFAOYSA-N 0.000 description 10
- 229960001653 citalopram Drugs 0.000 description 10
- 208000024732 dysthymic disease Diseases 0.000 description 10
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 10
- IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 10
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 10
- 229960002464 fluoxetine Drugs 0.000 description 10
- 229960004038 fluvoxamine Drugs 0.000 description 10
- 229960002073 sertraline Drugs 0.000 description 10
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 9
- 208000020401 Depressive disease Diseases 0.000 description 9
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 9
- 229950004874 binedaline Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229960000584 citalopram hydrobromide Drugs 0.000 description 9
- 229960001623 desvenlafaxine Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 229960004341 escitalopram Drugs 0.000 description 9
- 229960005437 etoperidone Drugs 0.000 description 9
- 229950003930 femoxetine Drugs 0.000 description 9
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 9
- 229960002107 fluvoxamine maleate Drugs 0.000 description 9
- 229950006314 ifoxetine Drugs 0.000 description 9
- 229960004333 indeloxazine Drugs 0.000 description 9
- 229960000600 milnacipran Drugs 0.000 description 9
- 229960001800 nefazodone Drugs 0.000 description 9
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 229960003660 sertraline hydrochloride Drugs 0.000 description 9
- 229960003991 trazodone Drugs 0.000 description 9
- 239000000935 antidepressant agent Substances 0.000 description 8
- 230000036651 mood Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 206010012374 Depressed mood Diseases 0.000 description 7
- 102000010909 Monoamine Oxidase Human genes 0.000 description 7
- 108010062431 Monoamine oxidase Proteins 0.000 description 7
- 208000028017 Psychotic disease Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 208000020925 Bipolar disease Diseases 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 3
- 206010049119 Emotional distress Diseases 0.000 description 3
- 206010016948 Food interaction Diseases 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 201000004810 Vascular dementia Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000003104 endogenous depression Diseases 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- 206010011971 Decreased interest Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 206010013496 Disturbance in attention Diseases 0.000 description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- 206010016759 Flat affect Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027374 Mental impairment Diseases 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010042458 Suicidal ideation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000013404 behavioral symptom Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 206010020765 hypersomnia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
- OJSFTALXCYKKFQ-PXNSSMCTSA-N (3s,4r)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine Chemical compound C1=CC(OC)=CC=C1OC[C@H]1[C@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-PXNSSMCTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SWGZHHCRMZDRSN-BTJKTKAUSA-N (Z)-but-2-enedioic acid 1-phenoxypropan-2-ylhydrazine Chemical compound OC(=O)\C=C/C(O)=O.NNC(C)COC1=CC=CC=C1 SWGZHHCRMZDRSN-BTJKTKAUSA-N 0.000 description 1
- LZTSCEYDCZBRCJ-UHFFFAOYSA-N 1,2-dihydro-1,2,4-triazol-3-one Chemical compound OC=1N=CNN=1 LZTSCEYDCZBRCJ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- HBWAYDBIHKCBLG-UHFFFAOYSA-N 1-propan-2-yl-2-(pyridin-4-ylmethyl)hydrazine Chemical compound CC(C)NNCC1=CC=NC=C1 HBWAYDBIHKCBLG-UHFFFAOYSA-N 0.000 description 1
- YTLUQMVDOGTESV-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-propan-2-ylacetohydrazide Chemical compound CC(C)N(N)C(=O)COC1=CC=C(Cl)C=C1 YTLUQMVDOGTESV-UHFFFAOYSA-N 0.000 description 1
- MVHRZTCXGAFVOF-UHFFFAOYSA-N 2-(cyclopropylamino)-1-naphthalen-2-ylethanone Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)CNC1CC1 MVHRZTCXGAFVOF-UHFFFAOYSA-N 0.000 description 1
- BWYDQVGGIRXHDE-UHFFFAOYSA-N 2-(cyclopropylamino)-1-phenylethanone Chemical compound C=1C=CC=CC=1C(=O)CNC1CC1 BWYDQVGGIRXHDE-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VGKDLMBJGBXTGI-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C12=CC=CC=C2C(NC)CCC1C1=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-UHFFFAOYSA-N 0.000 description 1
- RTLGMUXJYFSHMM-UHFFFAOYSA-N 4-(5-chloro-1-benzofuran-2-yl)-1-methylpiperidine;hydrochloride Chemical compound Cl.C1CN(C)CCC1C1=CC2=CC(Cl)=CC=C2O1 RTLGMUXJYFSHMM-UHFFFAOYSA-N 0.000 description 1
- SOGPAFXIVBGXFL-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-2-yl)piperidine Chemical compound C=1C2=CC(OC)=CC=C2OC=1C1CCNCC1 SOGPAFXIVBGXFL-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 1
- 101710185917 Amine oxidase [flavin-containing] A Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000011644 Neurologic Gait disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 101710171573 Primary amine oxidase Proteins 0.000 description 1
- 206010037249 Psychotic behaviour Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 102000015009 alpha1-adrenergic receptor activity proteins Human genes 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229940047493 celexa Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940009622 luvox Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229940110127 marplan Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- CIXAXTCLHPURJH-UHFFFAOYSA-N n',n'-dimethyl-n-(3-phenylindol-1-yl)propane-1,3-diamine Chemical compound C12=CC=CC=C2N(NCCCN(C)C)C=C1C1=CC=CC=C1 CIXAXTCLHPURJH-UHFFFAOYSA-N 0.000 description 1
- MUWKAPGYHBLRER-UHFFFAOYSA-N n-[2-(2-chlorophenoxy)ethyl]cyclopropanamine Chemical compound ClC1=CC=CC=C1OCCNC1CC1 MUWKAPGYHBLRER-UHFFFAOYSA-N 0.000 description 1
- DMRMQLPETKMFTM-UHFFFAOYSA-N n-[2-(2-iodophenoxy)ethyl]cyclopropanamine Chemical compound IC1=CC=CC=C1OCCNC1CC1 DMRMQLPETKMFTM-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229940087524 nardil Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 229940087824 parnate Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- YPDVTKJXVHYWFY-UHFFFAOYSA-N phosphoric acid;n'-propan-2-ylpyridine-4-carbohydrazide Chemical compound OP(O)(O)=O.CC(C)NNC(=O)C1=CC=NC=C1 YPDVTKJXVHYWFY-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940022817 venlafaxine 150 mg Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- MJIBOYFUEIDNPI-HBNMXAOGSA-L zinc 5-[2,3-dihydroxy-5-[(2R,3R,4S,5R,6S)-4,5,6-tris[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]-2-[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxymethyl]oxan-3-yl]oxycarbonylphenoxy]carbonyl-3-hydroxybenzene-1,2-diolate Chemical class [Zn++].Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c([O-])c([O-])c2)c1 MJIBOYFUEIDNPI-HBNMXAOGSA-L 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention is in the field of pharmaceutical therapies for psychiatric disorders such as apathy, dementia, or depression.
- the invention provides, in general, methods and compositions for treating psychiatric disorders, for example, apathy, dementia, or depression, using combination therapies such as a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor, in combination with an anti-psychotic agent.
- combination therapies such as a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor, in combination with an anti-psychotic agent.
- a method of treating dementia, depression, or apathy in a human subject by administering a pharmaceutically effective amount of a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor, in combination with an anti-psychotic agent to the subject.
- the subject may for example have been diagnosed as being in need of such treatment in accordance with generally accepted clinical criteria, or criteria as disclosed herein.
- a pharmaceutically effective amount of a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor in combination with an anti-psychotic agent for the preparation of a medicament for treating dementia, depression, or apathy.
- a pharmaceutical composition for treating dementia, depression, or apathy including a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor in combination with an anti-psychotic agent.
- the pharmaceutical composition may also comprise a pharmaceutically acceptable carrier.
- kits for treating dementia, depression, or apathy including a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor in combination with an anti-psychotic agent.
- the monoamine oxidase inhibitor may be a reversible monoamine oxidase inhibitor, for example, a reversible monoamine oxidase-A inhibitor, such as moclobemide, brofaromine, befloxatone, or toloxatone;
- the selective serotonin reuptake inhibitor may be fluoxetine, citalopram, fluvoxamine, sertraline, or paroxetine;
- the anti-psychotic agent may for example be an atypical anti-psychotic agent, for example, risperidone, olanzapine, zotepine, ziprasidone, quetiapine, sertindole, or clozapine.
- the monoamine oxidase inhibitor may for example be selected from the group: isocarboxazid; pargyline; selegiline; furazolidone; phenelzine; amiflamine; iproniazid; nialamide; tranylcypromine; octamoxin; phenoxypropazine; pivalyl benzhydrazine; iproclozide; iproniazide; bifemelane; prodipine; benmoxin; etryptamine; fenoxypropazine; mebanazine; pheniprazine; safrazine; hypericine; iproniazid phosphate; phenelzine sulphate; tranylcypromine sulphate; moclobemide; brofaromine; befloxatone; toloxatone; clorgyline; L 51.
- the selective serotonin reuptake inhibitor may for example be selected from the group: fluoxetine; citalopram; fluvoxamine; sertraline; paroxetine; escitalopram; femoxetine; ifoxetine; indeloxazine; binedaline; nefazodone; trazodone; etoperidone; milnacipran; venlafaxine; desvenlafaxine; citalopram hydrobromide; fluoxetine hydrochloride; fluvoxamine maleate; paroxetine hydrochloride; sertraline hydrochloride; mixtures thereof; and pharmaceutically acceptable salts thereof.
- the combination may be synergistically effective at reducing any of the indications of dementia, depression, or apathy.
- the composition may include moclobemide at a daily dosage of about 150 mg to about 600 mg, and any one of risperidone at a daily dosage of about 0.625 mg to about 3 mg, olanzapine at a daily dosage of about 0.625 mg to about 10 mg, zotepine at a daily dosage of about 12.5 mg to about 300 mg, ziprasidone at a daily dosage of about 1.00 mg to about 80 mg, quetiapine at a daily dosage of about 12.5 mg to about 800 mg, sertindole at a daily dosage of about 6.25 mg to about 450 mg or clozapine at a daily dosage of about 1.00 mg to about 900 mg, per day, respectively.
- the composition may include venlafaxine at a daily dosage of about 37.5 mg to about 375 mg, and any one of risperidone at a daily dosage of about 0.625 mg to about 3 mg, olanzapine at a daily dosage of about 0.625 mg to about 10 mg, zotepine at a daily dosage of about 12.5 mg to about 300 mg, ziprasidone at a daily dosage of about 1.00 mg to about 80 mg, quetiapine at a daily dosage of about 12.5 mg to about 800 mg, sertindole at a daily dosage of about 6.25 mg to about 450 mg or clozapine at a daily dosage of about 1.00 mg to about 900 mg, per day, respectively.
- a “pharmaceutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic or prophylactic result, such as reduction of any of the indications of dementia, depression, or apathy.
- a pharmaceutically effective amount of a combination of a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor and an anti-psychotic agent, according to the invention may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the combination to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic or prophylactic response.
- a pharmaceutically effective amount is also generally one in which any toxic or detrimental effects of the combination are outweighed by the therapeutically or prophylactically beneficial effects, although an assessment of benefit or detriment may vary according to the severity of the condition to be treated.
- a “synergistically effective” combination of a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor with an anti-psychotic agent is characterised by the fact that the monoamine oxidase inhibitor or the selective serotonin reuptake inhibitor is administered in a pharmaceutically effective amount and the anti-psychotic agent is administered in a pharmaceutically effective amount also, and the therapeutic effect thereby achieved, such as a reduction of any of the indications of dementia, depression, or apathy, is greater than the sum of the therapeutic effect that would be achieved with the monoamine oxidase inhibitor or the selective serotonin reuptake inhibitor alone in the pharmaceutically effective amount plus the therapeutic effect that would be achieved with the anti-psychotic agent alone in the pharmaceutically effective amount.
- a synergistically effective combination of risperidone and moclobemide is a combination wherein the moclobemide is administered in a pharmaceutically effective amount and risperidone is administered in a pharmaceutically effective amount, and the therapeutic effect on the indications of dementia, depression, or apathy thereby achieved is greater than the sum of the inhibition that would be achieved with risperidone alone in the pharmaceutically effective amount plus the inhibition that would be achieved with moclobemide alone in the pharmaceutically effective amount.
- a synergistically effective combination of olanzapine and venlafaxine is a combination wherein the venlafaxine is administered in a pharmaceutically effective amount and olanzapine is administered in a pharmaceutically effective amount, and the therapeutic effect on the indications of dementia, depression, or apathy thereby achieved is greater than the sum of the inhibition that would be achieved with olanzapine alone in the pharmaceutically effective amount plus the inhibition that would be achieved with venlafaxine alone in the pharmaceutically effective amount.
- Treating”, “treatment” or “to treat” as used herein means the medical management of a subject, usually a human subject, with the intent that a cure, amelioration, or prevention of dementia, depression, or apathy will result.
- This term includes active treatment, that is, treatment directed specifically toward improvement of dementia, depression, or apathy, and also includes causal treatment, that is, treatment directed toward removal of dementia, depression, or apathy.
- palliative treatment that is, treatment designed for the relief of symptoms rather than the curing of dementia, depression, or apathy
- preventive treatment that is, treatment directed to prevention of dementia, depression, or apathy
- supportive treatment that is, treatment employed to supplement another specific therapy directed toward the improvement of dementia, depression, or apathy.
- the invention provides methods and compositions for treating dementia, depression, or apathy associated with diverse mental disorders.
- the compositions of the invention include a monoamine oxidase inhibitor (MAOI) or a selective serotonin reuptake inhibitor (SSRI) in combination with an anti-psychotic agent.
- MAOI monoamine oxidase inhibitor
- SSRI selective serotonin reuptake inhibitor
- Treatment of dementia, depression, or apathy using the combination compositions of the invention is more effective, in some embodiments, than that achieved in the absence of treatment (i.e., without employing exogenous agents or therapeutics) or by treatment with a MAOI or SSRI alone, or an anti-psychotic agent alone, wherein the combination is administered in a “synergistically effective” amount.
- the combination compositions of the invention are useful in treating forms of dementia, depression, or apathy that are refractory to treatment using other therapeutic approaches.
- a SSRI in combination with an anti-psychotic agent may be excluded as a therapy or prophylaxis, according to the invention, for any one or more of the disorders of dementia, depression, or apathy.
- a MAOI or a reversible inhibitor of monoamine oxidase A (RIMA), in combination with an antagonist or agonist of a 5-HT receptor, or an anti-psychotic agent may be excluded, for example, for the treatment of depression.
- a combination of phenelzine and miperidone may be excluded for the treatment of depression.
- a combination of moclobemide with an atypical anti-psychotic agent may be excluded from the treatment of depression.
- Dementia is a neurodegenerative disorder generally characterized as the loss of an individual's learning and cognitive abilities, and is usually accompanied by behavioral, psychological, and motor symptoms.
- a critical element of dementia is the deficiency in short- and long-term memory, associated with difficulties in abstract thought, faulty judgment, personality change, and other impairments of higher cortical function. These impairments are generally so severe that the patient cannot maintain normal social activities or relationships.
- the loss of cognitive skills and memory in dementia is slow, with mental deterioration taking place over years. Dementia is most common among the elderly, and is becoming more widespread as the populations of developing countries age.
- dementias have been enumerated. For example, cortical dementia, fronto-temporal dementia, Alzheimer's dementia, lewy body dementia, progressive dementia, vascular dementia, multi-infarct dementia, drug- or alcohol-related dementia, and Parkinson's-related dementia. Dementia may also result from head injury, cardiac arrest, radiation therapy for cancer, Acquired Immunodeficiency Syndrome (AIDS), Pick's disease, or Creutzfeldt-Jakob disease, including its variant form. Dementia is usually diagnosed according to its etiology, the two most common etiologies being Alzheimer's dementia and vascular dementia, for example, following stroke, in the elderly. Dementia is usually progressive and irreversible unless the etiology itself is treatable. Many patients have more than one type of dementia. A diagnosis of dementia generally involves ruling out major depressive disorder or delirium.
- Cognitive symptoms may include things such as loss of memory, orientation perception, language and impaired judgement.
- Secondary or behavioral symptoms may include such things as personality and behavioral changes where the patient is aggressive or verbally agitated.
- Patients with dementia are often treated with anti-psychotic agents, benzodiazepines, beta-blockers, SSRIs, anti-depressants, anti-convulsives, and dietary supplements with limited efficacy.
- Depression or depressive disorders generally manifest as feelings of intense sadness and despair that are not attributable to other causes, such as bereavement.
- Depressed patients may experience mental slowness and a loss of concentration, insomnia or hypersomnia, anorexia or weight gain, decreased energy and libido and disruption of normal circadian rhythms, body temperature and endocrine functions.
- the most common types of depression include unipolar or major depression, dysthymia, and bipolar disorder, which differ in the number of symptoms, severity, and persistence.
- “Unipolar depression” or “major depression” generally means a clinical course where an individual experiences a period of at least two weeks during which there is either depressed or irritable mood or a marked loss of interest or pleasure in almost all activities. In children and adolescents, the mood may more generally be irritable rather than sad. The individual also experiences at least four additional symptoms drawn from a list that includes significant changes in appetite or weight (e.g., a change of more than 5% of body weight in a month), sleep, and psychomotor activity; fatigue or loss of energy; feelings of worthlessness or inappropriate guilt (which may be delusional); difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts.
- significant changes in appetite or weight e.g., a change of more than 5% of body weight in a month
- sleep, and psychomotor activity e.g., a change of more than 5% of body weight in a month
- sleep, and psychomotor activity e.g., a change of more than
- Each symptom must be newly present or must have clearly worsened compared with the person's pre-episode status.
- the symptoms must persist for most of the day, nearly every day, for at least two consecutive weeks, and the episode must be accompanied by clinically significant distress or impairment in social, occupational (or academic), or other important areas of functioning.
- the episode may be a single episode or may be recurrent.
- Major depression is thus characterized by one or more major depressive episodes in an individual without a history of manic, mixed, or hypomanic episodes.
- the diagnosis of unipolar or major depression is not made if: manic, mixed, or hypomanic episodes develop during the course of depression; if the depression is due to the direct physiological effects of a substance; if the depression is due to the direct physiological effects of a general medical condition; if the depression is due to a bereavement or other significant loss (“reactive depression”); or if the episodes are better accounted for by schizoaffective disorder and are not superimposed on schizophrenia, schizophreniform disorder, delusional disorder, or psychotic disorder. If manic, mixed, or hypomanic episodes develop, then the diagnosis is changed to a bipolar disorder.
- Dysthymia is a less severe form of depression that involves a chronic malaise and exhibits many of the symptoms of major depression, but is not as disabling as is major depression. Dysthymia prevents an individual from functioning at his or her optimum level and is a long-term, low-grade disorder. An individual with dysthymia is likely to have at least one major depressive episode at some point. Thus, “dysthymia” or “dysthymic disorder” generally means a chronically depressed mood that occurs for most of the day, more days than not, for at least two years. In children and adolescents, the mood may be irritable rather than depressed, and the required minimum duration is one year.
- any symptom-free intervals last no longer than 2 months.
- at least two of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness.
- the symptoms may cause clinically significant distress or impairment in social, occupational (or academic), or other important areas of functioning.
- dysthymia The diagnosis of dysthymia is not made if: the individual has ever had a manic episode, a mixed episode, a hypomanic episode; has ever met the criteria for a cyclothymic disorder; the depressive symptoms occur exclusively during the course of a chronic psychotic disorder (e.g., schizophrenia); or if the disturbance is due to the direct physiological effects of a substance or a general medical condition. After the initial two-years of dysthymic disorder, major depressive episodes may be superimposed on the dysthymic disorder (“double depression”).
- Bipolar disorder also known as manic-depression, is characterized by severe mood swings, from high (mania) to low (depression). The mood swings may be abrupt or gradual. During the lows, an individual with bipolar disorder generally exhibits one or more of the symptoms of a depressive disorder.
- Depression is often co-morbid with chronic general medical conditions, for example, cancer, diabetes, heart disease, stroke, HIV/AIDS, Parkinson's disease, particularly in the elderly. Empirically, women are more likely to suffer from a form of depression than men. In addition to psychotherapy and electroconvulsive therapy, patients with a form of depression are often treated with tricyclic anti-depressants (TCAs), MAOIs, SSRIs, and psychotropic drugs.
- TCAs tricyclic anti-depressants
- Apathy is generally a behavioral disorder that is related to, but can be differentiated from, depression. Apathy is often defined as a lack of motivation not attributable to cognitive impairment, emotional distress, or decreased consciousness. Patients with apathy often have slowness of thinking and a decrease in their ability to refocus their thinking to accommodate a new topic. In addition, apathy is not a general decrease in cognitive function, but is rather associated with specific areas of cognitive dysfunction (Andersson S and A M Bergedalen, J Nerv Ment Dis 182:235-9, 1994; Kuzis et al. Neurology 52:1403-7, 1999).
- Apathy refers to a syndrome closely related to major depression in that apathy is characterized by a lack of feeling or emotion or indifference. However, Apathy may be distinguished from major depression by the absence of depressed mood.
- Apathy may also be of two types:
- Apathy may manifest during the course of unrelated neuropsychiatric disorders such as schizophrenia, Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington's Disease, HIV/AIDS, stroke, head injury, myotonic dystrophy, cerebrovascular lesions, and frontal lobe lesions. Diagnosing apathy in a patient requires that abulia, akinesia, akinetic mutism, depression, dementia, delirium, despair, and demoralization first be ruled out.
- agents such as methylphenidate, pemoline, dextroamphetamine, amantadine, amphetamine, bromocriptine, bupropion, or selegiline.
- DSM-IV-TR The Diagnostic and Statistical Manual of Mental Disorders IV-TR, Fourth Edition, Text Revision, Wash., American Psychiatric Association, 2000 (“DSM-IV-TR”) is commonly used among practitioners for diagnosing and treating mental disorders.
- An alternative standard for diagnosing mental disorders is provided by the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (“ICD-10”) under the aegis of the WHO.
- ICD-10 International Statistical Classification of Diseases and Related Health Problems
- the ICD criteria are perhaps more prevalent in Europe than in North America, although the DSM-IV-TR is used extensively internationally.
- the National Institute for Neurological Disorders and Stroke-Association Internationale pour labericht et l'Enseignement en Neurosciences (NINDS-AIREN) also maintains a standard for diagnosis of mental disorders.
- diagnoses of dementia, depression, or apathy according to the invention may be performed using criteria established by the DSM-IV-TR, ICD-10, NINDS-AIREN, the different apathy scales, or any other standard accepted by mental health practitioners. Diagnoses of dementia, depression, or apathy according to the invention may also be performed using newly established or experimental criteria.
- Apathy may be defined as a syndrome closely related to major depression in that apathy is characterized by a lack of feeling or emotion, or indifference. However, Apathy may be distinguished from major depression by the absence of depressed mood.
- MAOIs Monoamine oxidase inhibitors or MAOIs are a chemically heterogeneous class of anti-depressants that inhibit or affect the activity of monoamine oxidase in the brain, slowing the breakdown of monoamine neurotransmitters, thus affecting mood. Some non-selective MAO inhibitors have severe side effects, including adverse food and drug interactions. Some example of MAOIs include, but are not limited to the following:
- pargyline N-Methyl-N-propargylbenzylamine; CAS #555-57-7;
- phenelzine (Nardil® (Pfizer); CAS #51-71-8);
- amiflamine ((+/ ⁇ )-4-dimethylamino-a, 2-dimethylphenethylamine; Astra; CAS #77518-07-1);
- iproniazid isonicotinic acid-2-isopropylhydrazide; CAS #54-92-2;
- tranylcypromine (Parnate® (GlaxoSmithKline); CAS #155-09-9);
- octamoxin (1-methylheptyl-hydrazine; CAS #4687-87-1);
- iproniazide N-isonicotinyl-N′-isopropylhydrazine; CAS #54-92-2;
- bifemelane (4-(o-benzylphenoxy)-N-methylbutylamine (hydrochloride); CAS #90293-01-9);
- prodipine (1-(1-methylethyl)-4,4-diphenylpiperidine or 1-isopropyl-4,4-diphenylpiperidine; CAS #31314-38-2);
- etryptamine (a-ethyl-1H-indole-ethanamine; CAS #2235-90-7);
- pheniprazine (a-methylphenethyl-hydrazine (hydrochloride); CAS #55-52-7);
- Selective MAO A inhibitors include, but are not limited to the following:
- harmine (7-methoxy-1-methyl- ⁇ -carboline; CAS #442-51-3);
- harmaline (3,4-dihydro-7-methoxy-1-methyl- ⁇ -carboline; CAS #304-21-2);
- T-794 (Tanabe Seiyaku—[(5R)-3-(6-(cyclopropylmethoxy) 2-naphthalenyl)-5-(methoxymethyl) 2-oxazolidone]);
- sercloremine (4-(5-chloro-2-benzofuranyl)-1-methylpiperidine (hydrochloride) Novartis—Ciba-Geigy);
- Some of the selective MAO A inhibitors listed above may have mixed MAO A and MAO B inhibitory activity, may be a bioprecursor which liberates an MAO A inhibitor when administered and may also be reversible MAO inhibitor.
- Reversible inhibitors of monoamine oxidase Type A are a sub-class of MAOIs that preferentially inhibit isoenzyme A of monamine oxidase and are reversible. RIMAs are considered safer and substantially more free of side effects, perhaps because isoenzyme B remains available to metabolize tyramine, which is present in some foods.
- RIMA anti-depressants include, but are not limited to, moclobemide, brofaromine, befloxatone (Bristol-Myers Squibb; (R)-5-(methoxymethyl)-3-(p[(R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone; CAS #134564-82-2) and toloxatone.
- Moclobemide (Manerix® (Roche); p-chloro-N-(2-morpholinoethyl) benzamide; CAS #71320-77-9) is an anti-depressant that affects the monoaminergic cerebral neurotransmitter system in a reversible manner.
- moclobemide treatment patients generally have decreased metabolism of dopamine, norephinephrine and serotonin, therefore increasing the extracellular concentrations of these neurotransmitters.
- Moclobemide is often prescribed for major depression or in extreme cases of social phobia.
- Moclobemide's use in depression appears to have similar efficacy as that of TCAs, SSRIs, and non-selective irreversible MAOIs.
- moclobemide seems to have much fewer side effects than other anti-depressant treatments, as well as fewer food and drug interactions. For these reasons, moclobemide has been widely used as an anti-depressant.
- Brofaromine Consonar® (Novartis—Ciba-Geigy); 4-(5-methoxy-2 benzofuranyl)-piperidine; CAS #63638-91-5) described in U.S. Pat. No.
- Selective serotonin reuptake inhibitors or SSRIs are antidepressant agents that increase the levels of serotonin (5-hydroxytryptamine or 5-HT) in the body by blocking the presynaptic serotonin transporter receptor.
- SSRIs also affect the norepinephrine and/or the dopamine transporters, although to a lesser extent. Although SSRIs can have some side effects, including adverse food and drug interactions, in general they are considered more safe than older antidepressants and have been prescribed extensively.
- SSRIs While SSRIs have been primarily prescribed for anxiety disorders and unipolar and bipolar major depression, their use in the treatment of other psychiatric conditions such as dysthymia, premenstrual syndrome, bulimia nervosa, obesity, obsessive compulsive disorder, borderline personality disorder, alcoholism, rheumatic pain, and migraine headache has been supported.
- Examples of SSRIs include, but are not limited to the following:
- fluoxetine (3-[(p-trifluoromethyl)phenoxy]-N-methyl-3-phenylpropylamine (hydrochloride); CAS #54910-89-3);
- citalopram (Celexa®) (1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile; CAS #59729-33-8);
- paroxetine (Paxil®) ((3S-trans)-3-[(1,3-benzodioxol-5-yloxy) methyl]-4-(4-fluorophenyl)piperidine; CAS #61869-08-7);
- escitalopram (Cipralex®) ((S)-1-3-dimethylamino-propyl-1-(4′-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitril, oxalate);
- nefazodone (1-[3-[4-(m-chlorophenyl)-1-piperazinyl]propyl]-3-ethyl-4-(2-phenoxyethyl)- 2 -1,2,4-triazolin-5-one (HCl); CAS #83366-66-9);
- milnacipran ((+/ ⁇ )-cis-2-aminomethyl-N,N-diethyl-1-phenylcyclopropane-carboxamide (hydrochloride); CAS #92623-85-3);
- desvenlafaxine phenol, 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]-(Z)-2-butanedioate (1:1) monohydrate) (metabolite of venlafaxine);
- citalopram hydrobromide CAS #59729-32-7 for example: citalopram hydrobromide CAS #59729-32-7; fluoxetine hydrochloride CAS #59333-67-4; fluvoxamine maleate CAS #61718-82-9; paroxetine hydrochloride CAS #78246-49-8; and sertraline hydrochloride 79559-97-0).
- Anti-psychotic or neuroleptic agents are drugs that control agitated psychotic behavior, ameliorate disorders relating to thought and perception, and generally exert a calming effect.
- Atypical anti-psychotic or neuroleptic agents may be distinguished from “typical” anti-psychotic agents (for example, chlorpromazine or haloperidol) by their decreased extra-pyramidal side effects, especially dystonias.
- Atypical anti-psychotics or atypical neuroleptics often include serotonin-2(5-HT2) and dopamine-2(D2) receptor antagonists.
- atypical anti-psychotics include, without limitation, 5-HT1A agonists (for example, ziprasidone: 5-[2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, described in U.S. Pat. Nos.
- quetiapine 5-[2-(4-dibenzo[b, f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol, described in U.S. Pat. No. 4,879,288), 5-HT1A antagonists (for example, risperidone: 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]pyrimidin-4-one, described in U.S. Pat. No.
- sertindole 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]imidazolidin-2-one, described in U.S. Pat. Nos. 4,710,500, 5,112,838, and 5,238,945), and ⁇ 1-adrenoceptor antagonists (for example, clozapine: 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b, e][1,4]diazepine, described in U.S. Pat. No.
- 5-HT2 receptor for example, zotepine: 2-[(8-chlorodibenzo[b, f]thiepin-10-yl)oxy]-N,N-dimethylethylamine, described in British Patent 1,247,067, ziprasidone, quetiapine, sertindole, risperidone, and olanzapine).
- atypical anti-psychotics or neuroleptics is recommended at the lowest possible dose consistent with a therapeutic response to reduce emerging extra-pyramidal symptoms, to minimize frequency and severity of side effects and toxicity.
- Patients may be routinely assessed for breast tenderness or galactorrhea, as an alternative clinical monitoring technique, for evidence of increasing serum levels of atypical neuroleptics.
- Anti-psychotics for example, atypical anti-psychotics, have been used for a variety of indications, including treatment of schizophrenia, manic episodes of bipolar disorder, agitation and psychotic symptoms of dementia, Tourette's Syndrome, and other disorders that manifest psychotic or agitated symptoms.
- Subjects having or at risk for apathy, dementia, or depression may be administered a pharmaceutically effective amount of a MAOI, RIMA, or SSRI in combination with an anti-psychotic agent, for example, an atypical anti-psychotic agent, or pharmaceutically acceptable derivatives or salts thereof, formulated in a pharmaceutically acceptable carrier or diluent.
- an anti-psychotic agent for example, an atypical anti-psychotic agent, or pharmaceutically acceptable derivatives or salts thereof, formulated in a pharmaceutically acceptable carrier or diluent.
- a “pharmaceutically acceptable carrier” or “excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- compositions of the invention are well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. In some embodiments, supplementary active compounds can also be incorporated into the compositions.
- a “pharmaceutically acceptable salt” includes salts of a MAOI, RIMA, SSRI, or anti-psychotic agent derived from the combination of any of these agents and an organic or inorganic acid or base. Such agents are useful in both non-ionized and salt form. In practice, the use of a salt form amounts to use of a base form; both forms are within the scope of the invention.
- pharmaceutically acceptable salts or complexes refers to salts or complexes that retain the desired biological activity of the above-identified compounds and exhibit minimal undesired toxicological effects.
- Non-limiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with an organic cation formed from N,N-dibenzylethylene-diamine, D-glucosamine, ammonium, tetraethylammonium
- Any appropriate route of administration may be employed, for example, oral, parenteral, sublingual, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, or aerosol administration.
- Methods well known in the art for making formulations are described, for example, in “Remington: The Science and Practice of Pharmacy” (19 th ed.) ed. A. R. Gennaro, 1995, Mack Publishing Company, Easton, Pa., USA.
- the active compound(s) can also be administered through a transdermal patch (see, for example, Brown L. and Langer R.—Transdermal Delivery of Drugs, Annual Review of Medicine, 39:221-229 (1988)).
- Oral formulations generally include an inert diluent or an edible carrier.
- the active compound(s) may be incorporated with excipients and used, for example, in the form of tablets, troches, or capsules or liquids.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- Formulations for parenteral, intradermal, subcutaneous, or topical application may be in the form of liquid solutions or suspensions and may contain, for example, excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, propylene glycol or other synthetic solvents, oils of vegetable origin, fixed oils, or hydrogenated napthalenes, glycerine; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of toxicity such as sodium chloride or dextrose.
- excipients sterile water, saline, polyalkylene glycols such as polyethylene glycol, propylene glycol or other synthetic solvents, oils of vegetable origin, fixed oils, or hydrogenated napthalenes, glycerine
- antibacterial agents
- the carriers may be physiological saline or phosphate buffered saline (PBS).
- Intranasal formulations may be in the form of powders, nasal drops, or aerosols.
- Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
- slow release or extended release delivery systems may be utilized to protect the compound(s) against rapid elimination from the body.
- These include implants and microencapsulated delivery systems.
- Biocompatible, biodegradable polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
- Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes (see, for example, U.S. Pat. No. 4,522,811).
- the MAOI, RIMA, or SSRI may be administered in a separate formulation from the anti-psychotic agent, or atypical anti-psychotic agent, or may be administered in a single formulation.
- a single formulation containing both drugs may be used to improve patient compliance.
- individual formulations of the drugs may facilitate individual dosage adjustments.
- a preferred dosage range for pharmaceutically effective amounts of the compounds may be delivered to achieve peak plasma concentrations of any value between 0.1 nM-0.1M, 0.1 nM-0.05M, 0.05 nM-15 ⁇ M, or 0.01 nM-1 ⁇ M.
- concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other standard factors.
- Daily dosages of each of the active compound(s) may range from about 0.1 to about 5000 mg, or from about 0.5 to about 1000 mg, or 1 to 500 mg, or 10 to 100 mg.
- the compound may administered in any suitable unit dosage form of active ingredient.
- the combination of the MAOI, RIMA, or SSRI and the anti-psychotic agent, or atypical anti-psychotic agent will be at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more effective in treating apathy, dementia, or depression, than any of the compounds alone.
- dosage values may vary with the severity of the condition to be alleviated.
- specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions.
- Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners.
- the amount of active compound in the composition may vary according to factors such as the disease-state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
- Dosage unit form refers to physically discrete units suited as unitary dosages for subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment in individuals.
- the compound(s) are administered in a dosage sufficient to deliver to a patient a therapeutically or prophylactically effective amount without causing serious toxic effects, although in particularly severe disorders a certain amount of toxicity or side effects may be tolerated.
- compositions and kits described herein for the treatment of apathy, dementia, or depression may utilize or comprise a combination of one or more monoamine oxidase inhibitors in combination with one or more atypical anti-psychotic agents.
- the methods, uses, pharmaceutical compositions and kits described herein for the treatment of apathy, dementia, or depression may utilize or comprise a combination of one or more selective serotonin reuptake inhibitors in combination with one or more atypical anti-psychotic agents.
- such compositions may be in separate formulations or may be administered in a single formulation.
- active agents described herein as monoamine oxidase inhibitors, selective serotonin reuptake inhibitors and atypical anti-psychotic agents may take the form of a metabolite or a precursor, which when metabolised forms an active agent.
- Representative examples of single monoamine oxidase inhibitors or single selective serotonin reuptake inhibitors in combination with an atypical anti-psychotic agent are shown in TABLE 1 below.
- bifemelane ziprasidone 16. prodipine ziprasidone 17. benmoxin ziprasidone 18. etryptamine ziprasidone 19. fenoxypropazine ziprasidone 20. mebanazine ziprasidone 21. pheniprazine ziprasidone 22. safrazine ziprasidone 23. hypericine ziprasidone 24. iproniazid phosphate ziprasidone 25. phenelzine sulphate ziprasidone 26. tranylcypromine sulphate ziprasidone 27. moclobemide ziprasidone 28. brofaromine ziprasidone 29. befloxatone ziprasidone 30. toloxatone ziprasidone 31.
- desvenlafaxine ziprasidone 65 desvenlafaxine ziprasidone 65. citalopram hydrobromide ziprasidone 66. fluoxetine hydrochloride ziprasidone 67. fluvoxamine maleate ziprasidone 68. paroxetine hydrochloride ziprasidone 69. sertraline hydrochloride ziprasidone 70. isocarboxazid quetiapine 71. pargyline quetiapine 72. selegiline quetiapine 73. furazolidone quetiapine 74. phenelzine quetiapine 75. amiflamine quetiapine 76. iproniazid quetiapine 77. nialamide quetiapine 78.
- trazodone quetiapine 130 etoperidone quetiapine 131. milnacipran quetiapine 132. venlafaxine quetiapine 133. desvenlafaxine quetiapine 134. citalopram hydrobromide quetiapine 135.
- fluoxetine hydrochloride quetiapine 136 fluvoxamine maleate quetiapine 137. paroxetine hydrochloride quetiapine 138. sertraline hydrochloride quetiapine 139. isocarboxazid risperidone 140. pargyline risperidone 141. selegiline risperidone 142.
- prodipine risperidone 155 benmoxin risperidone 156. etryptamine risperidone 157. fenoxypropazine risperidone 158. mebanazine risperidone 159. pheniprazine risperidone 160. safrazine risperidone 161. hypericine risperidone 162. iproniazid phosphate risperidone 163. phenelzine sulphate risperidone 164. tranylcypromine sulphate risperidone 165. moclobemide risperidone 166.
- sertindole 220 iproclozide sertindole 221. iproniazide sertindole 222. bifemelane sertindole 223. prodipine sertindole 224. benmoxin sertindole 225. etryptamine sertindole 226. fenoxypropazine sertindole 227. mebanazine sertindole 228. pheniprazine sertindole 229. safrazine sertindole 230. hypericine sertindole 231.
- citalopram sertindole 258 fluvoxamine sertindole 259. sertraline sertindole 260. paroxetine sertindole 261. escitalopram sertindole 262. femoxetine sertindole 263. ifoxetine sertindole 264. indeloxazine sertindole 265. binedaline sertindole 266. nefazodone sertindole 267. trazodone sertindole 268. etoperidone sertindole 269. milnacipran sertindole 270.
- AZAprine clozapine 314. BW-1370U87 clozapine 315.
- E-2011 clozapine 316. harmine clozapine 317. harmaline clozapine 318.
- esuprone clozapine 324. clorgyline hydrochloride clozapine 325.
- iproniazide olanzapine 429 bifemelane olanzapine 430. prodipine olanzapine 431. benmoxin olanzapine 432. etryptamine olanzapine 433. fenoxypropazine olanzapine 434. mebanazine olanzapine 435. pheniprazine olanzapine 436. safrazine olanzapine 437. hypericine olanzapine 438. iproniazid phosphate olanzapine 439. phenelzine sulphate olanzapine 440.
- a pharmaceutical composition is prepared by combining moclobemide with any one of risperidone, olanzapine, zotepine, ziprasidone, quetiapine, sertindole, or clozapine in a pharmaceutically acceptable carrier.
- the composition includes moclobemide at a daily dosage of about 75 mg to about 600 mg, and any one of risperidone at a daily dosage of about 0.25 mg to about 3 mg, olanzapine at a daily dosage of about 0.625 mg to about 10 mg, zotepine at a daily dosage of about 12.5 mg to about 300 mg, ziprasidone at a daily dosage of about 1.00 mg to about 80 mg, quetiapine at a daily dosage of about 12.5 mg to about 800 mg, sertindole at a daily dosage of about 6.25 mg to about 450 mg or clozapine at a daily dosage of about 1.00 mg to about 900 mg, per day, respectively.
- the composition is administered to a patient for treating dementia, depression, or apathy.
- a pharmaceutical composition is prepared by combining moclobemide with any one of risperidone, olanzapine, zotepine, ziprasidone, quetiapine, sertindole, or clozapine in a pharmaceutically acceptable carrier.
- the composition includes moclobemide at a daily dosage of about 150 mg to about 600 mg, and any one of risperidone at a daily dosage of about 0.625 mg to about 3 mg, olanzapine at a daily dosage of about 0.625 mg to about 10 mg, zotepine at a daily dosage of about 12.5 mg to about 300 mg, ziprasidone at a daily dosage of about 1.00 mg to about 80 mg, quetiapine at a daily dosage of about 12.5 mg to about 800 mg, sertindole at a daily dosage of about 6.25 mg to about 450 mg or clozapine at a daily dosage of about 1.00 mg to about 900 mg, per day, respectively.
- the composition is administered to a patient for treating dementia, depression, or apathy.
- a pharmaceutical composition is prepared by combining venlafaxine with any one of risperidone, olanzapine, zotepine, ziprasidone, quetiapine, sertindole, or clozapine in a pharmaceutically acceptable carrier.
- the composition includes venlafaxine at a daily dosage of about 37.5 mg to about 375 mg, and any one of risperidone at a daily dosage of about 0.25 mg to about 3 mg, olanzapine at a daily dosage of about 0.625 mg to about 10 mg, zotepine at a daily dosage of about 12.5 mg to about 300 mg, ziprasidone at a daily dosage of about 1.00 mg to about 80 mg, quetiapine at a daily dosage of about 12.5 mg to about 800 mg, sertindole at a daily dosage of about 6.25 mg to about 450 mg or clozapine at a daily dosage of about 1.00 mg to about 900 mg, per day, respectively.
- the composition is administered to a patient for treating dementia, depression, or apathy.
- the composition is prepared with risperidone at a daily dosage of about 0.625 mg to about 3 mg.
- a pharmaceutical composition is prepared by combining venlafaxine with any one of risperidone, olanzapine, zotepine, ziprasidone, quetiapine, sertindole, or clozapine in a pharmaceutically acceptable carrier.
- the composition includes venlafaxine at a daily dosage of about 37.5 mg to about 375 mg, and any one of risperidone at a daily dosage of about 0.625 mg to about 3 mg, olanzapine at a daily dosage of about 0.625 mg to about 10 mg, zotepine at a daily dosage of about 12.5 mg to about 300 mg, ziprasidone at a daily dosage of about 1.00 mg to about 80 mg, quetiapine at a daily dosage of about 12.5 mg to about 800 mg, sertindole at a daily dosage of about 6.25 mg to about 450 mg or clozapine at a daily dosage of about 1.00 mg to about 900 mg, per day, respectively.
- the composition is administered to a patient for treating dementia, depression, or apathy.
- a treatment plan for apathy was made whereby low dose moclobemide was titrated against low dose risperidone, commenced approximately 6 months following the initial diagnosis. Subsequently (approximately 2 months later), improvement was independently documented.
- the combination therapy (moclobemide and risperidone or olanzapine) exhibited a clinical efficacy that appeared to be greater than the cumulative effect that would have been expected if the patient had been treated with an equivalent amount of moclobemide alone or with an equivalent amount of risperidone or olanzapine alone.
- a 49 year female was diagnosed at a specialized clinic with early onset Alzheimer's disease in 2001. Donepezil 10 mg daily was commenced. The clinical picture was complicated by a degree of anxiety and depressed mood. The depressed mood responded to venlafaxine 150 mg daily. The anxiety improved by systematically addressing life course issues.
- Moclobemide was commenced day 4 at 75 mg. daily, increased to 150 mg. daily on day 8 and decreased to 75 mg daily on day 11. Olanzapine was commenced day 8 at 1.25 mg daily and continued at that dose.
- Salient medical history included a remote mastectomy for breast cancer, three vessel coronary bypass, acid peptic disease and hypertension.
- Moclobemide was commenced at 200 mg. daily on day 4, increased to 300 mg. daily and day 6 and continued at 300 mg. daily.
- Risperidone was commenced at 0.5 mg daily on day 7, discontinued on day 14 then restarted at 0.5 mg daily alternating with 0.25 mg. daily and continued as such.
- the first three days of the admission showed prominent depressed mood in the morning with very limited improvement in the late afternoon.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
TABLE 1 | |||
monoamine oxidase inhibitor or | |||
a selective serotonin reuptake | atypical anti- | ||
inhibitor | psychotic agent | ||
1. | isocarboxazid | ziprasidone |
2. | pargyline | ziprasidone |
3. | selegiline | ziprasidone |
4. | furazolidone | ziprasidone |
5. | phenelzine | ziprasidone |
6. | amiflamine | ziprasidone |
7. | iproniazid | ziprasidone |
8. | nialamide | ziprasidone |
9. | tranylcypromine | ziprasidone |
10. | octamoxin | ziprasidone |
11. | phenoxypropazine | ziprasidone |
12. | pivalyl benzhydrazine; | ziprasidone |
13. | iproclozide | ziprasidone |
14. | iproniazide | ziprasidone |
15. | bifemelane | ziprasidone |
16. | prodipine | ziprasidone |
17. | benmoxin | ziprasidone |
18. | etryptamine | ziprasidone |
19. | fenoxypropazine | ziprasidone |
20. | mebanazine | ziprasidone |
21. | pheniprazine | ziprasidone |
22. | safrazine | ziprasidone |
23. | hypericine | ziprasidone |
24. | iproniazid phosphate | ziprasidone |
25. | phenelzine sulphate | ziprasidone |
26. | tranylcypromine sulphate | ziprasidone |
27. | moclobemide | ziprasidone |
28. | brofaromine | ziprasidone |
29. | befloxatone | ziprasidone |
30. | toloxatone | ziprasidone |
31. | clorgyline | ziprasidone |
32. | L 51. 641 | ziprasidone |
33. | L 54. 761 | ziprasidone |
34. | L 54. 832 | ziprasidone |
35. | LY 121. 768 | ziprasidone |
36. | cimoxatone | ziprasidone |
37. | bazinaprine | ziprasidone |
38. | BW-1370U87 | ziprasidone |
39. | E-2011 | ziprasidone |
40. | harmine | ziprasidone |
41. | harmaline | ziprasidone |
42. | RS-8359 | ziprasidone |
43. | T-794 | ziprasidone |
44. | MDL 72394 | ziprasidone |
45. | MDL 72392 | ziprasidone |
46. | sercloremine | ziprasidone |
47. | esuprone | ziprasidone |
48. | clorgyline hydrochloride | ziprasidone |
49. | fluoxetine | ziprasidone |
50. | citalopram | ziprasidone |
51. | fluvoxamine | ziprasidone |
52. | sertraline | ziprasidone |
53. | paroxetine | ziprasidone |
54. | escitalopram | ziprasidone |
55. | femoxetine | ziprasidone |
56. | ifoxetine | ziprasidone |
57. | indeloxazine | ziprasidone |
58. | binedaline | ziprasidone |
59. | nefazodone | ziprasidone |
60. | trazodone | ziprasidone |
61. | etoperidone | ziprasidone |
62. | milnacipran | ziprasidone |
63. | venlafaxine | ziprasidone |
64. | desvenlafaxine | ziprasidone |
65. | citalopram hydrobromide | ziprasidone |
66. | fluoxetine hydrochloride | ziprasidone |
67. | fluvoxamine maleate | ziprasidone |
68. | paroxetine hydrochloride | ziprasidone |
69. | sertraline hydrochloride | ziprasidone |
70. | isocarboxazid | quetiapine |
71. | pargyline | quetiapine |
72. | selegiline | quetiapine |
73. | furazolidone | quetiapine |
74. | phenelzine | quetiapine |
75. | amiflamine | quetiapine |
76. | iproniazid | quetiapine |
77. | nialamide | quetiapine |
78. | tranylcypromine | quetiapine |
79. | octamoxin | quetiapine |
80. | phenoxypropazine | quetiapine |
81. | pivalyl benzhydrazine; | quetiapine |
82. | iproclozide | quetiapine |
83. | iproniazide | quetiapine |
84. | bifemelane | quetiapine |
85. | prodipine | quetiapine |
86. | benmoxin | quetiapine |
87. | etryptamine | quetiapine |
88. | fenoxypropazine | quetiapine |
89. | mebanazine | quetiapine |
90. | pheniprazine | quetiapine |
91. | safrazine | quetiapine |
92. | hypericine | quetiapine |
93. | iproniazid phosphate | quetiapine |
94. | phenelzine sulphate | quetiapine |
95. | tranylcypromine sulphate | quetiapine |
96. | moclobemide | quetiapine |
97. | brofaromine | quetiapine |
98. | befloxatone | quetiapine |
99. | toloxatone | quetiapine |
100. | clorgyline | quetiapine |
101. | L 51. 641 | quetiapine |
102. | L 54. 761 | quetiapine |
103. | L 54. 832 | quetiapine |
104. | LY 121. 768 | quetiapine |
105. | cimoxatone | quetiapine |
106. | bazinaprine | quetiapine |
107. | BW-1370U87 | quetiapine |
108. | E-2011 | quetiapine |
109. | harmine | quetiapine |
110. | harmaline | quetiapine |
111. | RS-8359 | quetiapine |
112. | T-794 | quetiapine |
113. | MDL 72394 | quetiapine |
114. | MDL 72392 | quetiapine |
115. | sercloremine | quetiapine |
116. | esuprone | quetiapine |
117. | clorgyline hydrochloride | quetiapine |
118. | fluoxetine | quetiapine |
119. | citalopram | quetiapine |
120. | fluvoxamine | quetiapine |
121. | sertraline | quetiapine |
122. | paroxetine | quetiapine |
123. | escitalopram | quetiapine |
124. | femoxetine | quetiapine |
125. | ifoxetine | quetiapine |
126. | indeloxazine | quetiapine |
127. | binedaline | quetiapine |
128. | nefazodone | quetiapine |
129. | trazodone | quetiapine |
130. | etoperidone | quetiapine |
131. | milnacipran | quetiapine |
132. | venlafaxine | quetiapine |
133. | desvenlafaxine | quetiapine |
134. | citalopram hydrobromide | quetiapine |
135. | fluoxetine hydrochloride | quetiapine |
136. | fluvoxamine maleate | quetiapine |
137. | paroxetine hydrochloride | quetiapine |
138. | sertraline hydrochloride | quetiapine |
139. | isocarboxazid | risperidone |
140. | pargyline | risperidone |
141. | selegiline | risperidone |
142. | furazolidone | risperidone |
143. | phenelzine | risperidone |
144. | amiflamine | risperidone |
145. | iproniazid | risperidone |
146. | nialamide | risperidone |
147. | tranylcypromine | risperidone |
148. | octamoxin | risperidone |
149. | phenoxypropazine | risperidone |
150. | pivalyl benzhydrazine; | risperidone |
151. | iproclozide | risperidone |
152. | iproniazide | risperidone |
153. | bifemelane | risperidone |
154. | prodipine | risperidone |
155. | benmoxin | risperidone |
156. | etryptamine | risperidone |
157. | fenoxypropazine | risperidone |
158. | mebanazine | risperidone |
159. | pheniprazine | risperidone |
160. | safrazine | risperidone |
161. | hypericine | risperidone |
162. | iproniazid phosphate | risperidone |
163. | phenelzine sulphate | risperidone |
164. | tranylcypromine sulphate | risperidone |
165. | moclobemide | risperidone |
166. | brofaromine | risperidone |
167. | befloxatone | risperidone |
168. | toloxatone | risperidone |
169. | clorgyline | risperidone |
170. | L 51. 641 | risperidone |
171. | L 54. 761 | risperidone |
172. | L 54. 832 | risperidone |
173. | LY 121. 768 | risperidone |
174. | cimoxatone | risperidone |
175. | bazinaprine | risperidone |
176. | BW-1370U87 | risperidone |
177. | E-2011 | risperidone |
178. | harmine | risperidone |
179. | harmaline | risperidone |
180. | RS-8359 | risperidone |
181. | T-794 | risperidone |
182. | MDL 72394 | risperidone |
183. | MDL 72392 | risperidone |
184. | sercloremine | risperidone |
185. | esuprone | risperidone |
186. | clorgyline hydrochloride | risperidone |
187. | fluoxetine | risperidone |
188. | citalopram | risperidone |
189. | fluvoxamine | risperidone |
190. | sertraline | risperidone |
191. | paroxetine | risperidone |
192. | escitalopram | risperidone |
193. | femoxetine | risperidone |
194. | ifoxetine | risperidone |
195. | indeloxazine | risperidone |
196. | binedaline | risperidone |
197. | nefazodone | risperidone |
198. | trazodone | risperidone |
199. | etoperidone | risperidone |
200. | milnacipran | risperidone |
201. | venlafaxine | risperidone |
202. | desvenlafaxine | risperidone |
203. | citalopram hydrobromide | risperidone |
204. | fluoxetine hydrochloride | risperidone |
205. | fluvoxamine maleate | risperidone |
206. | paroxetine hydrochloride | risperidone |
207. | sertraline hydrochloride | risperidone |
208. | isocarboxazid | sertindole |
209. | pargyline | sertindole |
210. | selegiline | sertindole |
211. | furazolidone | sertindole |
212. | phenelzine | sertindole |
213. | amiflamine | sertindole |
214. | iproniazid | sertindole |
215. | nialamide | sertindole |
216. | tranylcypromine | sertindole |
217. | octamoxin | sertindole |
218. | phenoxypropazine | sertindole |
219. | pivalyl benzhydrazine; | sertindole |
220. | iproclozide | sertindole |
221. | iproniazide | sertindole |
222. | bifemelane | sertindole |
223. | prodipine | sertindole |
224. | benmoxin | sertindole |
225. | etryptamine | sertindole |
226. | fenoxypropazine | sertindole |
227. | mebanazine | sertindole |
228. | pheniprazine | sertindole |
229. | safrazine | sertindole |
230. | hypericine | sertindole |
231. | iproniazid phosphate | sertindole |
232. | phenelzine sulphate | sertindole |
233. | tranylcypromine sulphate | sertindole |
234. | moclobemide | sertindole |
235. | brofaromine | sertindole |
236. | befloxatone | sertindole |
237. | toloxatone | sertindole |
238. | clorgyline | sertindole |
239. | L 51. 641 | sertindole |
240. | L 54. 761 | sertindole |
241. | L 54. 832 | sertindole |
242. | LY 121. 768 | sertindole |
243. | cimoxatone | sertindole |
244. | bazinaprine | sertindole |
245. | BW-1370U87 | sertindole |
246. | E-2011 | sertindole |
247. | harmine | sertindole |
248. | harmaline | sertindole |
249. | RS-8359 | sertindole |
250. | T-794 | sertindole |
251. | MDL 72394 | sertindole |
252. | MDL 72392 | sertindole |
253. | sercloremine | sertindole |
254. | esuprone | sertindole |
255. | clorgyline hydrochloride | sertindole |
256. | fluoxetine | sertindole |
257. | citalopram | sertindole |
258. | fluvoxamine | sertindole |
259. | sertraline | sertindole |
260. | paroxetine | sertindole |
261. | escitalopram | sertindole |
262. | femoxetine | sertindole |
263. | ifoxetine | sertindole |
264. | indeloxazine | sertindole |
265. | binedaline | sertindole |
266. | nefazodone | sertindole |
267. | trazodone | sertindole |
268. | etoperidone | sertindole |
269. | milnacipran | sertindole |
270. | venlafaxine | sertindole |
271. | desvenlafaxine | sertindole |
272. | citalopram hydrobromide | sertindole |
273. | fluoxetine hydrochloride | sertindole |
274. | fluvoxamine maleate | sertindole |
275. | paroxetine hydrochloride | sertindole |
276. | sertraline hydrochloride | sertindole |
277. | isocarboxazid | clozapine |
278. | pargyline | clozapine |
279. | selegiline | clozapine |
280. | furazolidone | clozapine |
281. | phenelzine | clozapine |
282. | amiflamine | clozapine |
283. | iproniazid | clozapine |
284. | nialamide | clozapine |
285. | tranylcypromine | clozapine |
286. | octamoxin | clozapine |
287. | phenoxypropazine | clozapine |
288. | pivalyl benzhydrazine; | clozapine |
289. | iproclozide | clozapine |
290. | iproniazide | clozapine |
291. | bifemelane | clozapine |
292. | prodipine | clozapine |
293. | benmoxin | clozapine |
294. | etryptamine | clozapine |
295. | fenoxypropazine | clozapine |
296. | mebanazine | clozapine |
297. | pheniprazine | clozapine |
298. | safrazine | clozapine |
299. | hypericine | clozapine |
300. | iproniazid phosphate | clozapine |
301. | phenelzine sulphate | clozapine |
302. | tranylcypromine sulphate | clozapine |
303. | moclobemide | clozapine |
304. | brofaromine | clozapine |
305. | befloxatone | clozapine |
306. | toloxatone | clozapine |
307. | clorgyline | clozapine |
308. | L 51. 641 | clozapine |
309. | L 54. 761 | clozapine |
310. | L 54. 832 | clozapine |
311. | LY 121. 768 | clozapine |
312. | cimoxatone | clozapine |
313. | bazinaprine | clozapine |
314. | BW-1370U87 | clozapine |
315. | E-2011 | clozapine |
316. | harmine | clozapine |
317. | harmaline | clozapine |
318. | RS-8359 | clozapine |
319. | T-794 | clozapine |
320. | MDL 72394 | clozapine |
321. | MDL 72392 | clozapine |
322. | sercloremine | clozapine |
323. | esuprone | clozapine |
324. | clorgyline hydrochloride | clozapine |
325. | fluoxetine | clozapine |
326. | citalopram | clozapine |
327. | fluvoxamine | clozapine |
328. | sertraline | clozapine |
329. | paroxetine | clozapine |
330. | escitalopram | clozapine |
331. | femoxetine | clozapine |
332. | ifoxetine | clozapine |
333. | indeloxazine | clozapine |
334. | binedaline | clozapine |
335. | nefazodone | clozapine |
336. | trazodone | clozapine |
337. | etoperidone | clozapine |
338. | milnacipran | clozapine |
339. | venlafaxine | clozapine |
340. | desvenlafaxine | clozapine |
341. | citalopram hydrobromide | clozapine |
342. | fluoxetine hydrochloride | clozapine |
343. | fluvoxamine maleate | clozapine |
344. | paroxetine hydrochloride | clozapine |
345. | sertraline hydrochloride | clozapine |
346. | isocarboxazid | zotepine |
347. | pargyline | zotepine |
348. | selegiline | zotepine |
349. | furazolidone | zotepine |
350. | phenelzine | zotepine |
351. | amiflamine | zotepine |
352. | iproniazid | zotepine |
353. | nialamide | zotepine |
354. | tranylcypromine | zotepine |
355. | octamoxin | zotepine |
356. | phenoxypropazine | zotepine |
357. | pivalyl benzhydrazine; | zotepine |
358. | iproclozide | zotepine |
359. | iproniazide | zotepine |
360. | bifemelane | zotepine |
361. | prodipine | zotepine |
362. | benmoxin | zotepine |
363. | etryptamine | zotepine |
364. | fenoxypropazine | zotepine |
365. | mebanazine | zotepine |
366. | pheniprazine | zotepine |
367. | safrazine | zotepine |
368. | hypericine | zotepine |
369. | iproniazid phosphate | zotepine |
370. | phenelzine sulphate | zotepine |
371. | tranylcypromine sulphate | zotepine |
372. | moclobemide | zotepine |
373. | brofaromine | zotepine |
374. | befloxatone | zotepine |
375. | toloxatone | zotepine |
376. | clorgyline | zotepine |
377. | L 51. 641 | zotepine |
378. | L 54. 761 | zotepine |
379. | L 54. 832 | zotepine |
380. | LY 121. 768 | zotepine |
381. | cimoxatone | zotepine |
382. | bazinaprine | zotepine |
383. | BW-1370U87 | zotepine |
384. | E-2011 | zotepine |
385. | harmine | zotepine |
386. | harmaline | zotepine |
387. | RS-8359 | zotepine |
388. | T-794 | zotepine |
389. | MDL 72394 | zotepine |
390. | MDL 72392 | zotepine |
391. | sercloremine | zotepine |
392. | esuprone | zotepine |
393. | clorgyline hydrochloride | zotepine |
394. | fluoxetine | zotepine |
395. | citalopram | zotepine |
396. | fluvoxamine | zotepine |
397. | sertraline | zotepine |
398. | paroxetine | zotepine |
399. | escitalopram | zotepine |
400. | femoxetine | zotepine |
401. | ifoxetine | zotepine |
402. | indeloxazine | zotepine |
403. | binedaline | zotepine |
404. | nefazodone | zotepine |
405. | trazodone | zotepine |
406. | etoperidone | zotepine |
407. | milnacipran | zotepine |
408. | venlafaxine | zotepine |
409. | desvenlafaxine | zotepine |
410. | citalopram hydrobromide | zotepine |
411. | fluoxetine hydrochloride | zotepine |
412. | fluvoxamine maleate | zotepine |
413. | paroxetine hydrochloride | zotepine |
414. | sertraline hydrochloride | zotepine |
415. | isocarboxazid | olanzapine |
416. | pargyline | olanzapine |
417. | selegiline | olanzapine |
418. | furazolidone | olanzapine |
419. | phenelzine | olanzapine |
420. | amiflamine | olanzapine |
421. | iproniazid | olanzapine |
422. | nialamide | olanzapine |
423. | tranylcypromine | olanzapine |
424. | octamoxin | olanzapine |
425. | phenoxypropazine | olanzapine |
426. | pivalyl benzhydrazine; | olanzapine |
427. | iproclozide | olanzapine |
428. | iproniazide | olanzapine |
429. | bifemelane | olanzapine |
430. | prodipine | olanzapine |
431. | benmoxin | olanzapine |
432. | etryptamine | olanzapine |
433. | fenoxypropazine | olanzapine |
434. | mebanazine | olanzapine |
435. | pheniprazine | olanzapine |
436. | safrazine | olanzapine |
437. | hypericine | olanzapine |
438. | iproniazid phosphate | olanzapine |
439. | phenelzine sulphate | olanzapine |
440. | tranylcypromine sulphate | olanzapine |
441. | moclobemide | olanzapine |
442. | brofaromine | olanzapine |
443. | befloxatone | olanzapine |
444. | toloxatone | olanzapine |
445. | clorgyline | olanzapine |
446. | L 51. 641 | olanzapine |
447. | L 54. 761 | olanzapine |
448. | L 54. 832 | olanzapine |
449. | LY 121. 768 | olanzapine |
450. | cimoxatone | olanzapine |
451. | bazinaprine | olanzapine |
452. | BW-1370U87 | olanzapine |
453. | E-2011 | olanzapine |
454. | harmine | olanzapine |
455. | harmaline | olanzapine |
456. | RS-8359 | olanzapine |
457. | T-794 | olanzapine |
458. | MDL 72394 | olanzapine |
459. | MDL 72392 | olanzapine |
460. | sercloremine | olanzapine |
461. | esuprone | olanzapine |
462. | clorgyline hydrochloride | olanzapine |
463. | fluoxetine | olanzapine |
464. | citalopram | olanzapine |
465. | fluvoxamine | olanzapine |
466. | sertraline | olanzapine |
467. | paroxetine | olanzapine |
468. | escitalopram | olanzapine |
469. | femoxetine | olanzapine |
470. | ifoxetine | olanzapine |
471. | indeloxazine | olanzapine |
472. | binedaline | olanzapine |
473. | nefazodone | olanzapine |
474. | trazodone | olanzapine |
475. | etoperidone | olanzapine |
476. | milnacipran | olanzapine |
477. | venlafaxine | olanzapine |
478. | desvenlafaxine | olanzapine |
479. | citalopram hydrobromide | olanzapine |
480. | fluoxetine hydrochloride | olanzapine |
481. | fluvoxamine maleate | olanzapine |
482. | paroxetine hydrochloride | olanzapine |
483. | sertraline hydrochloride | olanzapine |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/437,409 US8703764B2 (en) | 2003-12-02 | 2006-05-19 | Combination therapy for dementia, depression and apathy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52613703P | 2003-12-02 | 2003-12-02 | |
PCT/CA2004/002071 WO2005053703A1 (en) | 2003-12-02 | 2004-12-02 | Combination therapy for dementia, depression and apathy |
US11/437,409 US8703764B2 (en) | 2003-12-02 | 2006-05-19 | Combination therapy for dementia, depression and apathy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2004/002071 Continuation WO2005053703A1 (en) | 2003-12-02 | 2004-12-02 | Combination therapy for dementia, depression and apathy |
Publications (2)
Publication Number | Publication Date |
---|---|
US20060287299A1 US20060287299A1 (en) | 2006-12-21 |
US8703764B2 true US8703764B2 (en) | 2014-04-22 |
Family
ID=34652422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/437,409 Expired - Fee Related US8703764B2 (en) | 2003-12-02 | 2006-05-19 | Combination therapy for dementia, depression and apathy |
Country Status (3)
Country | Link |
---|---|
US (1) | US8703764B2 (en) |
EP (1) | EP1713486A4 (en) |
WO (1) | WO2005053703A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
US11207310B2 (en) | 2016-08-24 | 2021-12-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR042806A1 (en) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | COMBINATION OF CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE REABSORTION FOR THE TREATMENT OF ANIMO DISORDERS |
BR0317771A (en) | 2002-12-27 | 2005-11-22 | Otsuka Pharma Co Ltd | Pharmaceutical composition, use, and method of treating disorders in a patient |
WO2007027987A2 (en) | 2005-09-02 | 2007-03-08 | Mount Cook Biosciences, Inc. | Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity |
CA2677219A1 (en) * | 2007-02-01 | 2009-01-29 | Alan I. Green | Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade |
US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
WO2012099952A2 (en) | 2011-01-19 | 2012-07-26 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
JP2014508187A (en) * | 2011-03-17 | 2014-04-03 | ルピン・リミテッド | Controlled release pharmaceutical composition of selective serotonin reuptake inhibitor |
ES2879631T3 (en) | 2013-06-21 | 2021-11-22 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of Huntington's disease |
WO2017173067A1 (en) | 2016-03-31 | 2017-10-05 | Versi Group, Llc | Delta opioid agonist, mu opioid antagonist compositions and methods for treating parkinson's disease |
CN108938645A (en) * | 2018-08-24 | 2018-12-07 | 山西医科大学第医院 | A kind of antipsychotic drug compositions |
WO2023099554A1 (en) * | 2021-11-30 | 2023-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Derivatives of nifuroxazide for use in the treatment of mitochondrial disorders and neurodegenerative diseases |
US20230301903A1 (en) * | 2022-03-25 | 2023-09-28 | Neurelis, Inc. | Intranasal olanzapine formulations and methods of their use |
WO2023236781A1 (en) * | 2022-06-10 | 2023-12-14 | 上海日馨医药科技股份有限公司 | Method for treating mental diseases |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648396A (en) | 1991-02-04 | 1997-07-15 | Sepracor Inc. | Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor |
EP0830864A1 (en) | 1996-09-23 | 1998-03-25 | Eli Lilly And Company | Combination therapy for treatment of psychoses |
EP0958824A2 (en) | 1998-05-22 | 1999-11-24 | Eli Lilly And Company | Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
WO1999059593A1 (en) | 1998-05-21 | 1999-11-25 | Eli Lilly And Company | Combination therapy for treatment of depression |
WO1999062522A1 (en) | 1998-05-29 | 1999-12-09 | Eli Lilly And Company | Combination therapy for treatment of bipolar disorders |
WO2000006140A2 (en) | 1998-07-31 | 2000-02-10 | Vela Pharmaceuticals Inc. | Use of moclobemide for treating certain phsychiatric and medical disorders |
EP1016664A1 (en) | 1997-09-02 | 2000-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused thiophene compounds and medicinal use thereof |
US20020151543A1 (en) | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
US20020193429A1 (en) | 1998-04-14 | 2002-12-19 | Guochuan Tsai | Methods for treating neuropsychiatric disorders |
US20030032636A1 (en) | 1999-12-06 | 2003-02-13 | H. Lundbeck A/S | Combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist |
US6555585B2 (en) * | 2000-07-21 | 2003-04-29 | Teva Pharmaceutical Industries, Ltd. | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
WO2003066039A1 (en) | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
US20030212060A1 (en) | 1998-05-22 | 2003-11-13 | Tollefson Gary Dennis | Combination therapy for treatment of refractory depression |
US20040204401A1 (en) * | 2002-07-30 | 2004-10-14 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210754A (en) * | 1977-02-01 | 1980-07-01 | Hoffmann-La Roche Inc. | Morpholino containing benzamides |
CA1332151C (en) * | 1988-01-28 | 1994-09-27 | Roman Amrein | Use of a benzamide to treat cognitive disorder |
CA2022552A1 (en) * | 1990-08-02 | 1992-02-03 | James W. Tetrud | Antiparkinsonian compositions |
US5455254A (en) * | 1991-02-15 | 1995-10-03 | Mondadori; Cesare | Substituted benzofuranylpiperidine as a nootropic agent |
CA2219902A1 (en) * | 1995-05-30 | 1996-12-05 | Eli Lilly And Company | Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine for treating cognitive dysfunction |
CA2364211A1 (en) * | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
-
2004
- 2004-12-02 WO PCT/CA2004/002071 patent/WO2005053703A1/en active Application Filing
- 2004-12-02 EP EP04802248A patent/EP1713486A4/en not_active Ceased
-
2006
- 2006-05-19 US US11/437,409 patent/US8703764B2/en not_active Expired - Fee Related
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648396A (en) | 1991-02-04 | 1997-07-15 | Sepracor Inc. | Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor |
EP0830864A1 (en) | 1996-09-23 | 1998-03-25 | Eli Lilly And Company | Combination therapy for treatment of psychoses |
EP1016664A1 (en) | 1997-09-02 | 2000-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused thiophene compounds and medicinal use thereof |
US20020193429A1 (en) | 1998-04-14 | 2002-12-19 | Guochuan Tsai | Methods for treating neuropsychiatric disorders |
WO1999059593A1 (en) | 1998-05-21 | 1999-11-25 | Eli Lilly And Company | Combination therapy for treatment of depression |
WO1999061027A1 (en) * | 1998-05-22 | 1999-12-02 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
EP0958824A2 (en) | 1998-05-22 | 1999-11-24 | Eli Lilly And Company | Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
US20030212060A1 (en) | 1998-05-22 | 2003-11-13 | Tollefson Gary Dennis | Combination therapy for treatment of refractory depression |
US20020151543A1 (en) | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
WO1999062522A1 (en) | 1998-05-29 | 1999-12-09 | Eli Lilly And Company | Combination therapy for treatment of bipolar disorders |
WO2000006140A2 (en) | 1998-07-31 | 2000-02-10 | Vela Pharmaceuticals Inc. | Use of moclobemide for treating certain phsychiatric and medical disorders |
US20030032636A1 (en) | 1999-12-06 | 2003-02-13 | H. Lundbeck A/S | Combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist |
US6555585B2 (en) * | 2000-07-21 | 2003-04-29 | Teva Pharmaceutical Industries, Ltd. | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
WO2003066039A1 (en) | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
US20040204401A1 (en) * | 2002-07-30 | 2004-10-14 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
Non-Patent Citations (31)
Title |
---|
Adler et al., "Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide" J. of Geriatric Psychiatry, vol. 18, No. 7, pp. 653-655 (2003). |
Amrein et al, "Moclobemide in Patients with Dementia and Depression," Parkinson's Disease: Advance in Neurology (1999) 80:509-519. |
Breitbart, W et al., "Neuropsychiatric Syndromes and Psychological Symptoms in Patients with Advanced Cancer" Journal of Pain and Symptom Management vol. 10, No. 2 (1995) pp. 131-141. |
CA 02364211 A1. * |
De Deyn et al. "A Randomized Trial of Risperidone, Placebo, and Haloperidol for Behavioral Symptoms of Dementia," Neurology (1999) 53:946-955. |
Entsuah et al. (J. Clin. Psychiatry 2001; 62: 869-877; abstract). * |
Gareri et al. "Conventional and Atypical Antipsychotics in the Elderly," http://www.medscape.com/viewarticle/457366 Feb. 28, 2005. |
Glenn, M.B., et al. "Cutoff score on the apathy evaluation scale in subjects with traumatic brain injury", Brain Inj, 2002, 16(6): 509-516. |
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205-213. * |
Katz et al. "Comparison of Risperidone and Placebo for Psychosis and Behavioral Disturbances Associated with Dementia: A Randomized, Double-Blind Trial," J. Clin Psychiatry (1999) 60:107-115. |
Kenneth Bender (Psychiatric Times, Aug. 1, 1999). * |
Kuzis, G. et al. "Neuropsychological correlates of apathy and depression in patients with dementia", Neurology, 1999, 52(7):1403-7. |
Mann, R.S. "Apathy: concept, syndrome, neural mechanisms, and treatment", Semin clin Neuropsychiatry, 1996, 1(4):304-314. |
Marangell et al. (J. Clin. Psychiatry 63: 5, May 2002; p. 391-395). * |
Marin et al. (J. Nerv. Ment. Dis. 182(4); p. 235-239, (1994). * |
Marin, R. S. (Am. J. Psychiatry 147:1, Jan. 1990). * |
Marin, R. S. Am. J. Psychiatry 147:1, Jan. 1990; p. 22-30. * |
Marin, R. S., et al. "Group differences in the relationship between apathy and depression", Journal of Nervous Mental Disorders, 1994, 182(4):235-9. |
Marin, R.S. "Apathy: concept, syndrome, neural mechanisms, and treatment", Semin clin Neuropsychiatry, 1996, 1(4):304-314. |
Padala et al. Treatment of Apathy with Methylphenidate. J. Neuropsychiatry Clin. Neurosci., 2007,19(1); pp. 81-83. * |
Pollak P., Rev Neurol (Paris). Abstract Only 2002 158 1:S125-31. |
Robert S. Marin (Seminars in Clinical Neuropsychiatry, vol. 1, No. 4 (Oct. 1996): pp. 304-314. * |
Robert, P.H., et al. "The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment", Int J Geriatr Psychiatry, 2002, 17(2):1099-105. |
Sajatovic et al. J. Clin. Psychiatry 62:9, Sep. 2001; p. 728-732. * |
Schatz "Olanzapine for Psychotic and Behavioral Disturbances in Alzheimer Disease," The Annals of Pharmacotherapy (2003) 37:1321-1324. |
Tariot et al. "Pharmacologic Therapy for Behavioral Symptoms of Alzheimer's Disease," Clinics in Geriatric Medicine (2001) 17(2):3599-376. |
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories, ed. by Beers and Berkow, pp. 1531-1538 and 1569-1570. * |
Tolbert et al. "Selegiline in Treatment of Behavariol and Cognitive Symptoms of Alzheimer Disease," The Annals of Pharmacotherapy (1996) 30:1122-1129. |
V. Chan-Palay "Depression and Senile Dementia of the Alzheimer Type: A Role for Moclobemide," Psychopharmacology (1992) 106:S137-S139. |
Van Reekum et al (J. Neuropsychiatry Clin. Neurosci., 2005, 17(1); p. 7-19. * |
Wasbes et al. "Potential of Moclobemide to Improve Cerebral Insufficiency Identified Using a Scopolamine Model of Aging and Dementia," Acta Psychiatr Scand (1990) 360:71-72. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
US11207310B2 (en) | 2016-08-24 | 2021-12-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
Also Published As
Publication number | Publication date |
---|---|
EP1713486A1 (en) | 2006-10-25 |
WO2005053703A1 (en) | 2005-06-16 |
EP1713486A4 (en) | 2009-04-29 |
US20060287299A1 (en) | 2006-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8703764B2 (en) | Combination therapy for dementia, depression and apathy | |
TWI245631B (en) | Pharmaceutical composition for treating or preventing chronic pain | |
US20050233010A1 (en) | Lithium combinations, and uses related thereto | |
CN107735081A (en) | For treating the method and medicine box of depression | |
JP2004517112A (en) | New drug combination | |
CN101198323A (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
EP2043648A1 (en) | Use of flibanserin for the treatment of sexual disorders in females | |
KR20190013846A (en) | Compositions and methods for treating negative symptoms in non-ambulatory patients | |
AU2018205121A1 (en) | Treatment regimens | |
JP2012522033A (en) | Low-dose pipamperon in the treatment of mood disorders | |
US20100317666A1 (en) | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | |
CN117377470A (en) | Use of mevidaline and other D1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychoses | |
SK14502000A3 (en) | New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol | |
US20060217394A1 (en) | Treatment of anhedonia | |
JP2004529850A (en) | Methods and compositions for the treatment and prevention of sexual dysfunction | |
JP2019516758A (en) | (2S) -1- [4- (3,4-Dichlorophenyl) piperidin-1-yl] -3- [2- (5-methyl-1,3,4-oxadiazole- for treating anxiety disorders 2-yl) benzo [b] furan-4-yloxy] propan-2-ol or a metabolite thereof | |
Post-MI | IV. MEDICAL CAUSES OF DEPRESSION | |
JP2007533699A (en) | Medicine | |
JP2007522175A (en) | 2-Methoxy-5- (5-trifluoromethyl-tetrazol-1-yl-benzyl) -2S-phenyl-piperidin-3S-yl) amine for the treatment of social phobia | |
WO2012072665A1 (en) | Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors | |
JP2005060286A (en) | Treatment of schizophrenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220422 |